Acotiamide

Acotiamide
Clinical data
Trade names	Acofide (JP)
Routes of; administration	By mouth (tablets)
ATC code	None;
Legal status
Legal status	Rx-only (JP);
Pharmacokinetic data
Protein binding	84.21–85.95%
Metabolism	UGT1A8 and 1A9 (major)
Elimination half-life	10.9–21.7 hours
Excretion	Feces (92.7%), urine (5.3%)
Identifiers
	IUPAC name N-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide;
CAS Number	185106-16-5 ;
PubChem CID	5282338;
ChemSpider	4445505 ;
UNII	D42OWK5383;
KEGG	D08838 ;
ChEMBL	ChEMBL2107723 ;
Chemical and physical data
Formula	C21H30N4O5S
Molar mass	450.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O;
	InChI InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27) ; Key:TWHZNAUBXFZMCA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Acotiamide (brand name Acofide, codenamed YM-443 and Z-338) is a drug manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.^[2] It acts as an acetylcholinesterase inhibitor. It is pending approval in the United States; ten clinical trials have been successfully completed.

References

↑ "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
↑ Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698. S2CID 41298446.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.

[2] Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698. S2CID 41298446.

[1]

[2]